Draupnir Bio is a Danish biotechnology company founded in 2017 as a spin-out from Aarhus University, Denmark, and the Max-Planck Society, Germany.
Location: Denmark, Capital Region of Denmark, Copenhagen
Employees: 11-50
Total raised: $13.13M
Founded date: 2017
Investors 2
| Date | Name | Website |
| 07.05.2025 | MP Healthc... | mp-healthc... |
| - | High-Tech ... | htgf.de |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.07.2024 | Seed | $13.13M | - |
Mentions in press and media 4
| Date | Title | Description |
| 15.10.2024 | Q3 2024’s Seed deal boom: Europe’s top tech startups to watch | The Tech.eu Q3 2024 Report reveals that European tech companies raised €11 billion across 891 deals during the third quarter. Approximately 14% of these companies successfully closed seed rounds, amounting to nearly half a billion euros (€4... |
| 22.07.2024 | Draupnir Bio Completes €12M Seed Funding | Draupnir Bio, a Copehagen, Denmark-based biotechnology company harnessing the natural machinery of the lysosome to develop oral, small molecule degraders of extracellular disease-causing proteins, raised €12M in Seed funding. Backers includ... |
| 17.07.2024 | Draupnir Bio completes €12 million seed round to progress development of oral small molecule degraders of extracellular proteins | - |
| - | Draupnir Bio | “Draupnir Bio is developing new innovative therapies for patients.” |